SU11248 is a selective inhibitor of certain protein kinases including VEGFR types 1-3 that are expressed in human breast cancer. The present study determines whether the anti-tumor activity of SU11248 results from the inhibition of angiogenesis, as well as direct anti-proliferation and anti-migration effects on breast tumors. Eight-wk old female mice (C57BL/6) were given SU11248 at 20-40 mg/kg/d in drinking (distilled) water for 4 wks. Control mice received drinking water only. In the 2nd wk, 10(6) E0771 (mouse breast cancer) cells were injected in the left fourth mammary gland. Tumor size was monitored using dial calipers. At the end, tumors were isolated for measuring tumor size and intratumoral microvessel density (IMD) using CD31 immunohistochemistry. SU11248 significantly reduced tumor weight over the control (1.22 ± 0.28 vs. 3.28 ± 0.31 g; n = 8; p < 0.01) and IMD (111 ± 10 vs. 155 ± 6 IM#/mm2; p < 0.01). RT-PCR indicated that VEGFR1 and R2 were expressed in cultured E0771 cells. VEGF (10 ng/ml) caused a 42% increase in proliferation of E0771 cells, compared to the control (p < 0.01; n = 8), and there was a significant decrease in proliferation of E0771 cells treated with VEGF plus SU11248 (10 μmol/L) vs. the control (65%, p < 0.01). VEGF caused a 2-fold increase in the proliferation of HUVEC vs. the control (p < 0.01; n = 8), but its action was completely eradicated by SU11248. Neither VEGF nor SU11248 had any effect on the proliferation of cultured HAS MC. Migration assay showed that SU11248 (10 μmol/L) significantly inhibited the migration of cultured E0771 cells. SU11248 significantly inhibited the proliferation of MCF-7 and MDAMB-231 cells in a dose-related manner. These findings support the hypothesis that the antitumor activity of SU11248 on breast cancer is possibly mediated by targeting the paracrine and autocrine effects of VEGF on breast cancer to suppress tumor angiogenesis, proliferation and migration.
Vascular endothelial growth factor (VEGF) is a well known angiogenic factor that has been suggested to play some physiological roles in reproductive organs. To clarify whether VEGF is involved in regulating bovine endometrial function locally, in experiment 1, we determined the expression of VEGF, VEGF receptor (VEGFR) 1 and VEGFR2 throughout the estrous cycle in endometrial tissues. Endometrial tissue was collected at estrus (Day 0), the early I (Days 2-3), early II (Days 5-6), mid (Days 8-12) and late luteal stages (Days 15-17) and the follicular stage (Days 19-21). RT-PCR and Western blotting analysis revealed that VEGF mRNA expression at estrus was higher than at the early I, early II and late luteal stages (P<0.05), whereas VEGF protein content was greatest at the early I luteal stage and decreased thereafter. VEGFR1 mRNA expression was lower at estrus and at the early I and early II luteal stages than at the other stages, whereas VEGFR1 protein expression did not change significantly throughout the estrous cycle (P<0.05). VEGFR2 mRNA expression was higher at the mid and late luteal stages than at the early I and early II luteal stages, and VEGFR2 protein was higher at the mid and late luteal stages than at estrus (P<0.05). In experiment 2, to determine the effect of VEGF on prostaglandin (PG) F2alpha and PGE2 production by endometrial cells, cultured endometrial epithelial and stromal cells were exposed to VEGF (0, 5, 50, 100 and 200 ng/ml) for 24 h. VEGF (200 ng/ml) stimulated PGF2alpha production by stromal cells (P<0.05), but not PGE2 production. VEGF did not affect PG production by endometrial epithelial cells. The overall results suggest that VEGF and its receptors are regulated throughout the estrous cycle and that VEGF participates in the local regulation of bovine endometrial function by a selective modulation of PGF2alpha production in stromal cells in an auto- and/or paracrine manner.
